HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury.

Abstract
Traumatic brain injury (TBI) is a leading cause of morbidity and mortality in young people in industrialized countries. Although various anti-inflammatory and antiapoptotic modalities have shown neuroprotective effects in experimental models of TBI, to date, no specific pharmacological agent aimed at blocking the progression of secondary brain damage has been approved for clinical use. Erythropoietin (Epo) belongs to the cytokine superfamily and has traditionally been viewed as a hematopoiesis-regulating hormone. The newly discovered neuroprotective properties of Epo lead us to investigate its effect in TBI in a mouse model of closed head injury. Recombinant human erythropoietin (rhEpo) was injected at 1 and 24 h after TBI, and the effect on recovery of motor and cognitive functions, tissue inflammation, axonal degeneration, and apoptosis was evaluated up to 14 days. Motor deficits were lower, cognitive function was restored faster, and less apoptotic neurons and caspase-3 expression were found in rhEpo-treated as compared with vehicle-treated animals (P<0.05). Axons at the trauma area in rhEpo-treated mice were relatively well preserved compared with controls (shown by their density; P<0.01). Immunohistochemical analysis revealed a reduced activation of glial cells by staining for GFAP and complement receptor type 3 (CD11b/CD18) in the injured hemisphere of Epo- vs. vehicle-treated animals. We propose that further studies on Epo in TBI should be conducted in order to consider it as a novel therapy for TBI.
AuthorsI Yatsiv, N Grigoriadis, C Simeonidou, P F Stahel, O I Schmidt, A G Alexandrovitch, J Tsenter, E Shohami
JournalFASEB journal : official publication of the Federation of American Societies for Experimental Biology (FASEB J) Vol. 19 Issue 12 Pg. 1701-3 (Oct 2005) ISSN: 1530-6860 [Electronic] United States
PMID16099948 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Inflammatory Agents
  • CD11b Antigen
  • CD18 Antigens
  • Cytokines
  • Glial Fibrillary Acidic Protein
  • Recombinant Proteins
  • Erythropoietin
  • CASP3 protein, human
  • Casp3 protein, mouse
  • Casp3 protein, rat
  • Caspase 3
  • Caspases
Topics
  • Animals
  • Anti-Inflammatory Agents (pharmacology)
  • Apoptosis
  • Axons (metabolism)
  • Brain (pathology)
  • CD11b Antigen (biosynthesis)
  • CD18 Antigens (biosynthesis)
  • Caspase 3
  • Caspases (metabolism)
  • Cytokines (metabolism)
  • Disease Models, Animal
  • Erythropoietin (chemistry, metabolism, pharmacology, physiology)
  • Glial Fibrillary Acidic Protein (metabolism)
  • Head Injuries, Closed (pathology)
  • Hematopoiesis
  • Immunohistochemistry
  • In Situ Nick-End Labeling
  • Inflammation
  • Male
  • Mice
  • Neurons (metabolism, pathology)
  • Rats
  • Recombinant Proteins (chemistry)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: